Aclaris Therapeutics (NASDAQ:ACRS) Posts Earnings Results, Misses Expectations By $0.03 EPS

Aclaris Therapeutics (NASDAQ:ACRS) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03), Zacks reports. The firm had revenue of $4.35 million for the quarter, compared to analysts’ expectations of $8.31 million. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%.

Aclaris Therapeutics Stock Up 8.4 %

Shares of ACRS traded up $0.19 during midday trading on Thursday, reaching $2.45. The company had a trading volume of 1,005,888 shares, compared to its average volume of 998,016. Aclaris Therapeutics has a 1-year low of $0.59 and a 1-year high of $5.61. The firm has a 50 day simple moving average of $1.32 and a 200-day simple moving average of $1.24. The stock has a market cap of $174.80 million, a PE ratio of -2.99 and a beta of 0.10.

Analyst Ratings Changes

ACRS has been the topic of several recent research reports. HC Wainwright reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th. StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. One analyst has rated the stock with a sell rating and six have given a hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.